Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...

One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

this time in first-line treatment of advanced ovarian cancer. Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease ...

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...

In two Phase III trials the chemo potentiating effect of PARP inhibitors on other drugs is being investigated. The recent observation that HR can be downregulated by hyperthermia treatment holds ...

1 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 2 Department of Obstetrics and Gynecology, Taizhou Hospital of Zhejiang Province ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

The genetic testing results also inform patients’ family members about their cancer risks so they can be proactive in screening and prevention. For now, GENETECA™ is only available to people with ...

Treatment with a novel potent PARP inhibitor, starting after the time of islet destruction, maintained normal vascular responsiveness, despite the persistence of severe hyperglycemia. Endothelial ...